- Home
- SSY vs VIRX Comparison
SSY vs VIRX Comparison
Compare SSY & VIRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSY
- VIRX
- Stock Information
- Founded
- SSY 1959
- VIRX 2007
- Country
- SSY United States
- VIRX United States
- Employees
- SSY N/A
- VIRX N/A
- Industry
- SSY Hospital/Nursing Management
- VIRX Biotechnology: Pharmaceutical Preparations
- Sector
- SSY Health Care
- VIRX Health Care
- Exchange
- SSY Nasdaq
- VIRX Nasdaq
- Market Cap
- SSY 5.3M
- VIRX 6.3M
- IPO Year
- SSY N/A
- VIRX N/A
- Fundamental
- Price
- SSY $0.77
- VIRX $0.21
- Analyst Decision
- SSY
- VIRX Buy
- Analyst Count
- SSY 0
- VIRX 4
- Target Price
- SSY N/A
- VIRX $5.00
- AVG Volume (30 Days)
- SSY 17.6K
- VIRX 3.9M
- Earning Date
- SSY 02-11-2025
- VIRX 11-13-2024
- Dividend Yield
- SSY N/A
- VIRX N/A
- EPS Growth
- SSY N/A
- VIRX N/A
- EPS
- SSY N/A
- VIRX N/A
- Revenue
- SSY $31,808,000.00
- VIRX N/A
- Revenue This Year
- SSY N/A
- VIRX N/A
- Revenue Next Year
- SSY N/A
- VIRX N/A
- P/E Ratio
- SSY N/A
- VIRX N/A
- Revenue Growth
- SSY N/A
- VIRX N/A
- 52 Week Low
- SSY $0.53
- VIRX $0.13
- 52 Week High
- SSY $0.98
- VIRX $1.31
- Technical
- Relative Strength Index (RSI)
- SSY 47.08
- VIRX 60.26
- Support Level
- SSY $0.74
- VIRX $0.14
- Resistance Level
- SSY $0.88
- VIRX $0.19
- Average True Range (ATR)
- SSY 0.04
- VIRX 0.03
- MACD
- SSY -0.00
- VIRX 0.01
- Stochastic Oscillator
- SSY 21.36
- VIRX 83.12
About SSY SunLink Health Systems Inc.
SunLink Health Systems Inc is engaged in providing retail pharmacy services. The company operates its business through segments namely the Healthcare Services segment and Pharmacy segment. The Healthcare Services segment includes subsidiaries that own and operate licensed-bed, acute care hospitals, which includes bed geriatric psychology unit, and nursing home; own medical buildings, which are leased to unaffiliated healthcare providers, and adjacent vacant land; and provides information technology to outside customers. The Pharmacy segment, which is the key revenue generator is composed of retail pharmacy products and services that are conducted in rural markets; institutional pharmacy services; pharmacy services; and durable medical equipment.
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.